期刊文献+

乌司他丁在原发性肝癌介入治疗中保护肝功能的临床观察

Ulinastatin in the Protection of Liver Function in the Interventional Therapy of Primary Hepatic Carcinoma:Clinical Observation
原文传递
导出
摘要 目的:探讨乌司他丁在原发性肝癌介入治疗中的护肝作用。方法:将110例原发性肝癌患者随机分为治疗组与对照组。对照组给予常规药物治疗,治疗组在对照组治疗基础上加用乌司他丁治疗,监测2组肝功能变化及腹水生成情况。结果:介入治疗第3天治疗组丙氨酸氨基转移酶、天门冬酸氨基转移酶、总胆红素上升幅度均较对照组低(P<0·05);治疗第7天治疗组丙氨酸氨基转移酶、天门冬酸氨基转移酶显著低于对照组,总蛋白显著高于对照组(P<0·05)。2组腹水生成率无显著性差异(P>0·05)。结论:乌司他丁在原发性肝癌介入治疗中可产生显著的护肝作用。 OBJECTIVE: To discuss the effect of ulinastatin(UTI) in the protection of liver function in the interventional therapy of primary liver carcinoma.METHODS:A total of 110 patients with primary hepatic carcinoma were randomly assigned to receive routine therapy(control group) or routine therapy plus UTT(trial group), with liver functional changes and ascites formation of two groups monitored.RESULTS: On day 3 after interventional therapy, increases of ALT, AST and TBil in the trial group were lower than in the control group(P〈0.05),but on day 7,the ALT,AST and TBil were significantly lower and TP was significantly higher as compared with control group(P 〈 0.05).There was no significant difference in ascites formation rate between two groups(P〉0.05) .CONCLUSION:UTI showed a satisfactory effect in the protection of liver function in the interventional therapy for patients with primary hepatic carcinoma.
作者 黄冬 马晓鹂
出处 《中国药房》 CAS CSCD 北大核心 2007年第17期1336-1337,共2页 China Pharmacy
关键词 原发性肝癌 乌司他丁 介入治疗 Primary hepatic carcinoma Ulinastatin Interventional therapy
  • 引文网络
  • 相关文献

参考文献8

二级参考文献21

  • 1颜鸣,朱上林,林言箴.LAK、NK及T细胞亚群在肝癌手术前后的动态变化[J].中国医师杂志,2002,4(S1):6-8. 被引量:2
  • 2迟达超,韩希望,闫立昆,何文宪.乌司他丁对胃肠癌手术患者免疫功能的影响[J].第四军医大学学报,2004,25(15):1435-1437. 被引量:16
  • 3黎乐群,苏智雄,彭民浩,卢榜裕,彭涛,梁水庭,郭雅.手术打击对原发性肝癌病人术后免疫功能影响的研究[J].中华肝胆外科杂志,2004,10(6):420-421. 被引量:14
  • 4Okuhama Y, Shiraishi M, Higa T, et al. Protective effects of Ulinastastin against ischemia reperfusion injury [ J ]. J Surg Res, 1999, 82 ( 1 ) : 34-42.
  • 5王建华,腹部介入放射学,1998年,60页
  • 6Mckay CJ, Evans S, Sindair M, et al. High early morta-lity rate from acute pancreatitis[J]. Br J Surg, 2000, 87( 3): 379.
  • 7Brady M, Christmas S. Cytokine and acute pancreatitis[J].Baillieres Best Pract Res Clin Gastroenterol, 1999, 13( 2): 265.
  • 8Mager M, Rau B. Inflammatory mediators in human acute pancreatitis: Clinical and pathophysiological implications[J]. Gut, 2000, 47( 4): 546.
  • 9Lerch MM, Adler G. Experimental animal model of acute pancreatitis[J]. Inter J Pancreat, 1994, 15: 159.
  • 10Suzuki M, Kobayashi H, Tanaka Y. Structure and function analysis of urinary trypsin inhibitor( UTI) identification of binding domains and signaling property of UTI by analysis of truncated proteins[J]. Biochim Biophs Acta, 2001, 1 547( 1): 26.

共引文献1064

;
使用帮助 返回顶部